The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

Malvy, D., Taburet, A. M., de Lamballerie, X., Mentre, F., & Extramiana, F. (2020). The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Neglected Tropical Diseases, 14(6), 1–4. https://doi.org/10.1371/journal.pntd.0008259